http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Nodular Lymphoid Hyperplasia with Aggressive Endoscopic Appearance in the Colon of an Adult Woman
Maria Fragaki,Elpida Giannikaki,Emmanouil Vardas,Angeliki Theodoropoulou,Aikaterini Tavernaraki,Manousos Christodoulakis,Gregorios A. Paspatis 대한소화기내시경학회 2017 Clinical Endoscopy Vol.50 No.2
Brief report
Evangelos Voudoukis,Georgios Tribonias,Aikaterini Tavernaraki,Angeliki Theodoropoulou,Emmanouil Vardas,Konstantina Paraskeva,Gregorios Chlouverakis,Gregorios A. Paspatis 대한소화기내시경학회 2015 Clinical Endoscopy Vol.48 No.2
Background/Aims: Endoscopic mucosal resection (EMR) of large colorectal lesions is associated with increased procedural time. Theobjective of this study was to evaluate the effect of double-channel gastroscope (DCG) use on the procedural time of EMRs in the rectosigmoidarea. Methods: All EMRs for sessile or flat rectosigmoid lesions ≥2 cm performed between July 2011 and September 2012 were retrospectivelyanalyzed. Results: There were 55 lesions ≥2 cm in the rectosigmoid area in 55 patients, of which 26 were removed by EMR using a DCG (DCgroup) and 29 by using an ordinary colonoscope or gastroscope (OS group). The mean size of the removed polyps, morphology, adverseeffects, and other parameters were similar between the two groups. The mean procedural time was significantly lower in the DC groupthan in the OS group (24.4±18.3 minutes vs. 36.3±24.4 minutes, p=0.015). Moreover, in a subgroup of patients with polyps >40 mm, thestatistical difference in the mean procedural time between the DC and OS groups was even more pronounced (33±21 minutes vs. 58.7±20.6 minutes, p=0.004). Conclusions: Our data suggest that the use of a DCG in the resection of large nonpedunculated rectosigmoid lesions significantly reducesthe procedural time.
Long-Term (5 Years), High Daily Dosage of Dietary Agmatine—Evidence of Safety: A Case Report
Gad M. Gilad,Varda H. Gilad 한국식품영양과학회 2014 Journal of medicinal food Vol.17 No.11
There is presently a great interest in the therapeutic potential of agmatine, decarboxylated arginine, for various diseases. Recent clinical studies have already shown that oral agmatine sulfate given for up to 3 weeks provides a safe and, as compared with current therapeutics, more effective treatment for neuropathic pain. These studies have ushered in the use of dietary agmatine as a nutraceutical. However, in view of information paucity, assessment of long-term safety of oral agmatine treatment is now clearly required. The authors of this report undertook to assess their own health status during ongoing consumption of a high daily dosage of oral agmatine over a period of 4–5 years. A daily dose of 2.67 g agmatine sulfate was encapsulated in gelatin capsules; the regimen consists of six capsules daily, each containing 445mg, three in the morning and three in the evening after meals. Clinical follow-up consists of periodic physical examinations and laboratory blood and urine analyses. All measurements thus far remain within normal values and good general health status is sustained throughout the study period, up to 5 years. This case study shows for the first time that the recommended high dosage of agmatine may be consumed for at least 5 years without evidence of any adverse effects. These initial findings are highly important as they provide significant evidence for the extended long-term safety of a high daily dosage of dietary agmatine—a cardinal advantage for its utility as a nutraceutical.